US to donate 1 million mpox vaccine doses to halt outbreak in Africa

Published 09/24/2024, 05:25 AM
Updated 09/24/2024, 12:10 PM
© Reuters. FILE PHOTO: Undated handout picture of a Bavarian Nordic manufacturing line obtained by Reuters on August 16, 2024. Bavarian Nordic/Carsten Andersen/Handout via REUTERS/File Photo

By Trevor Hunnicutt and Julie Steenhuysen

WASHINGTON (Reuters) - U.S. President Joe Biden announced on Tuesday the donation of 1 million mpox vaccine doses and at least $500 million to African countries to support their response to the outbreak.

Biden made the announcement at the United Nations General Assembly in New York, and called on other countries to follow suit, confirming Reuters' earlier reporting.

"We must now move quickly to face mpox," Biden said.

In August, the World Health Organization declared mpox a global public health emergency for the second time in two years, following an outbreak of the viral infection in Democratic Republic of Congo that has spread to neighboring countries and beyond, including India, raising alarm.

"It wouldn't be a huge surprise if there were a case in the United States, either," a U.S. official said, noting that recent cuts in pandemic support by Congress may hamper a domestic response.

"We're really squeezing right now to be able to respond effectively in this moment. And I think anticipating potentially additional cuts in the future will make it more and more difficult for us to have a robust response to these types of outbreaks."

Mpox can spread through close contact. Usually mild, it is fatal in rare cases. It causes flu-like symptoms and pus-filled lesions on the body.

The outbreak in Congo began with the spread of an endemic strain, known as clade I. But a new variant, clade Ib, appears to spread more easily through routine close contact, including sexual contact.

Rich countries have several hundred million doses of vaccines that could help fight an mpox outbreak in Africa, where donated shots fall far short of what is needed, according to a Reuters tally of public statements, documents and estimates from non-governmental organizations.

The expectation is that the new U.S.-donated doses will be of the Bavarian Nordic vaccine known as Jynneos in the United States, and many will come from a U.S. stockpile.

The U.S. official said the administration expects Gavi, a public-private alliance which co-funds vaccine purchases for low-income countries, to distribute the donated vaccines.

"We feel really strongly that Gavi is the multilateral institution that is best positioned to procure and equitably distribute vaccines," the official said.

Last week, Gavi said it will buy 500,000 doses of Bavarian Nordic's vaccine, its first purchase to help battle the outbreak.

The Biden administration is also pushing for more vaccines to be manufactured in low and middle-income countries, and is working with Brazil to identify how the Group of 20 club of nations can support the mpox response.

© Reuters. FILE PHOTO: Undated handout picture of a Bavarian Nordic manufacturing line obtained by Reuters on August 16, 2024. Bavarian Nordic/Carsten Andersen/Handout via REUTERS/File Photo

There is not currently a manufacturer in Africa that is able to make the complex drug substance needed to make the vaccine, the U.S. official said.

"Most meaningful is Biden's public support for manufacturing capacity in lower-income countries to produce their own vaccines," said Lawrence Gostin, an expert in global health law at Georgetown University. "That will require Biden to press pharmaceutical companies to transfer technologies."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.